Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

BACKGROUND: Non-small cell lung cancer is a very poor prognosis disease. Molecular analyses have highlighted several genetic alterations which may be targeted by specific therapies. In clinical practice, progression-free survival on EGFR TKI treatment is between 12 and 14 months. However, some patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalens, Lorraine, Niogret, Julie, Richard, Corentin, Chevrier, Sandy, Foucher, Pascal, Coudert, Bruno, Lagrange, Aurélie, Favier, Laure, Westeel, Virginie, Kim, Stefano, Adotevi, Olivier, Chapusot, Caroline, Martin, Laurent, Arnould, Laurent, Kaderbhai, Courèche-Guillaume, Boidot, Romain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385908/
https://www.ncbi.nlm.nih.gov/pubmed/37516818
http://dx.doi.org/10.1186/s12943-023-01829-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385908/
https://www.ncbi.nlm.nih.gov/pubmed/37516818
http://dx.doi.org/10.1186/s12943-023-01829-4

Ejemplares similares